文献速递肾癌与肾肿瘤

双等位体细胞TSC2突变肾细胞癌:临床研究与文献综述

A Renal Cell Carcinoma with Biallelic Somatic TSC2 Mutation: Clinical Study and Literature Review.
PubMed 文献 · Urology · 2019-08-25

该研究报告一名14岁女性单侧孤立性肾细胞癌患者中检出两个新发体细胞TSC2突变,病理提示透明细胞肾细胞癌,免疫组化显示磷酸化S6K1升高。体外实验表明突变TSC2蛋白快速降解,无法抑制S6K1和STAT3磷酸化,导致mTORC1通路持续激活并促进肾细胞癌发生。结论提示早发肾细胞癌患者检测TSC2突变有益,mTOR抑制剂可作为TSC2突变所致肾细胞癌的治疗选择。

要点

  • 早发肾细胞癌患者应检测TSC2突变。
  • 双等位体细胞TSC2突变可致mTORC1通路持续激活。
  • mTOR抑制剂或为TSC2突变所致肾细胞癌的治疗选择。

核心结论

  • 早发肾细胞癌患者检测TSC2突变有益,mTOR抑制剂可作为TSC2突变所致肾细胞癌的治疗选择。

研究设计与样本

  • 对一名14岁女性单侧孤立性肾细胞癌样本进行突变分析、免疫组化和实时PCR,并开展体外细胞实验。

主要发现

  • 在14岁女性单侧孤立性肾细胞癌样本中检出两个新发体细胞TSC2突变。
  • 病理特征提示肿瘤为透明细胞肾细胞癌。
  • 免疫组化显示磷酸化S6K1水平升高。
  • 体外细胞实验提示突变TSC2蛋白快速降解,未能抑制S6K1和STAT3磷酸化,导致mTORC1通路持续激活并最终引起肾细胞癌发生。

临床怎么用

  • 对早发肾细胞癌患者可考虑检测TSC2突变。
  • 对TSC2突变所致肾细胞癌,mTOR抑制剂可作为治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To elucidate the effect of the biallelic somatic TSC2 mutations, identified in one adolescent patient, in renal cell carcinoma (RCC). METHODS: Mutation analyses, immunohistochemistry and real-time polymerase chain reaction (PCR) were conducted. RESULTS: Two novel somatic mutations of TSC2 in unilateral and solitary RCC samples from a 14-year-old female were identified. The pathological features suggest the tumor as a clear-cell renal cell carcinoma. In addition, immunohistochemistry revealed elevated levels of phosphorylated S6K1. Results from in vitro cellular experiments suggest that the mutant TSC2 proteins were quickly degraded and they failed to repress the phosphorylation of S6K1 and STAT3, which leads to constitutive activation of mTORC1 pathway and ultimately cause the development of RCC. CONCLUSION: Detecting TSC2 mutation in patients with early RCC onset would be beneficial and mTOR inhibitor could be a therapeutic option for TSC2 mutation-induced RCC.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Pang J, Wang L, Xu J, et al. A Renal Cell Carcinoma with Biallelic Somatic TSC2 Mutation: Clinical Study and Literature Review. Urology. 2019. PMID: 31454656. doi:10.1016/j.urology.2019.08.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。